An Objective Overview of Covid19 Vaccine Situation in India

Authors

  • Jay Sheth AMC MET Medical College, Ahmedabad
  • Kshem Prasad APT Progress, Puducherry, India
  • Tapasvi Puwar Indian Institute of Public Health, Gandhinagar, India

DOI:

https://doi.org/10.55489/njcm.1305202261

Keywords:

Covid19, Vaccination, India, Overview

Abstract

Entire world was eagerly waiting for the vaccine against SARS-CoV2 ever since Covid19 pandemic started. India is the second largest populous nation and is among the very few nations who has developed a vaccine against SARS-CoV2. India is also a major vaccine producing hub supplying large quantum of vaccines to the rest of the world. Efficacy, advantages and comparison between various covid vaccine has been largely discussed by the scientific community. However, there are various other factors affecting the vaccine situation in a nation, may it be the plan, strategy, it’s implementation, local context, health infrastructure etc. While there are many news and views related to covid-19 vaccine, one need to look beyond & into so many other aspects related to the factors affecting this situation. Through discussion of some of these key factors, we tried to draw an overall picture of the Covid19 vaccine situation in India. Keeping in line with our objective, we keep the focus of our discussion on vaccine development & manufacturing issues, diplomatic decisions on vaccine & the reasons behind the same, international factors etc. We have purposefully restricted our discussion to these factors and did not go in details of the national level policy and its implementation details in this article.

References

Munster V, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. New England Journal of Medicine. 2020;382(8):692-694. doi: https://doi.org/10.1056/NEJMp2000929 PMid:31978293

Wang L, He W, Yu X, Hu D, Bao M, Liu H et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. Journal of Infection. 2020;80(6):639-645. doi: https://doi.org/10.1016/j.jinf.2020.03.019 PMid:32240670 PMCid:PMC7118526

Chandra M. COVID-19 vaccines in less than a year - A new benchmark for human progress [Internet]. The Hindu. 2021 [cited 9 June 2021]. Available from: https://www.thehindu.com/sci-tech/health/covid-19-vaccines-in-less-than-a-year-a-new-benchmark-for-human-progress/article33541770.ece

Giordano G, Colaneri M, Di Filippo A, Blanchini F, Bolzern P, De Nicolao G et al. Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. Nature Medicine. 2021 doi: https://doi.org/10.1038/s41591-021-01334-5 PMid:33864052 PMCid:PMC8205853

Marín‐Hernández D, Schwartz R, Nixon D. Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID‐19 deaths in Italy. Journal of Medical Virology. 2020;93(1):64-65. doi: https://doi.org/10.1002/jmv.26120 PMid:32497290 PMCid:PMC7300995

Mahase E. Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate. BMJ. 2020;:m4347. doi: https://doi.org/10.1136/bmj.m4347 PMid:33168562

Knoll M, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. The Lancet. 2021;397(10269):72-74. doi: https://doi.org/10.1016/S0140-6736(20)32623-4

Deplanque D, Launay O. Efficacy of Covid-19 vaccines: from clinical trials to real life. Therapies. 2021 May 12. doi: https://doi.org/10.1016/j.therap.2021.05.004 PMid:34049688 PMCid:PMC8114590

Bob C. Get First COVID-19 Vaccine That's Available [Internet]. Healthline. 2021 [cited 9 June 2021]. Available from: https://www.healthline.com/health-news/why-you-should-take-the-first-covid-19-vaccine-thats-available-to-you

COVAXIN - India's First Indigenous Covid-19 Vaccine | Bharat Biotech [Internet]. Bharatbiotech.com. 2021 [cited 9 June 2021]. Available from: https://www.bharatbiotech.com/covaxin.html

Sharma J, Varshney SK. India's vaccine diplomacy aids global access to COVID-19 jabs. Nature India 2021. doi: 10.1038/nindia. 2021.31

Centre says open to facilitate Covaxin tech transfer to ramp up production [Internet]. The New Indian Express. 2021 [cited 9 June 2021]. Available from: https://www.newindianexpress.com/nation/2021/may/13/centre-says-open-to-facilitate-covaxin-tech-transfer-to-ramp-up-production-2302170.html

CDSCO. 11. [Internet]. Cdsco.gov.in. 2021 [cited 9 June 2021]. Available from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/biologicals/facilitiesLIST.pdf

The Lancet. Access to COVID-19 vaccines: looking beyond COVAX. The Lancet. 2021;397(10278):941. doi: https://doi.org/10.1016/S0140-6736(21)00617-6

Ministry of External Affairs-Government of India. Vaccine Supply [Internet]. Mea.gov.in. 2021 [cited 9 June 2021]. Available from: https://www.mea.gov.in/vaccine-supply.htm

Ahmad S. Serum Institute risks making Covid vaccine before trial at new $100 mn unit [Internet]. Business-standard.com. 2021 [cited 9 June 2021]. Available from: https://www.business-standard.com/article/current-affairs/serum-institute-risks-making-covid-vaccine-before-trial-at-new-100-mn-unit-120060501302_1.html

Bista R. 'Vaccine Scare' To 'Vaccine Apartheid' - Opposition Desperation Coming To The Fore [Internet]. Swarajyamag. 2021 [cited 9 June 2021]. Available from: https://swarajyamag.com/politics/vaccine-scare-to-vaccine-apartheid-opposition-desperation-coming-to-the-fore

Quint T. In January, PM Modi Had Expressed India's Victory Over COVID-19 [Internet]. TheQuint. 2021 [cited 9 June 2021]. Available from: https://www.thequint.com/news/india/in-january-pm-modi-had-expressed-indias-victory-over-covid-19

India's Second Wave: A Man-Made Disaster? [Internet]. Institut Montaigne. 2021 [cited 9 June 2021]. Available from: https://www.institutmontaigne.org/en/blog/indias-second-wave-man-made-disaster

Downloads

Published

2022-05-31

How to Cite

1.
Sheth J, Prasad K, Puwar T. An Objective Overview of Covid19 Vaccine Situation in India. Natl J Community Med [Internet]. 2022 May 31 [cited 2024 Mar. 28];13(05):342-5. Available from: https://www.njcmindia.com/index.php/file/article/view/61

Issue

Section

Commentary